Ocuphire Pharma (OCUP)
(Delayed Data from NSDQ)
$2.04 USD
+0.05 (2.51%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $2.05 +0.01 (0.49%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OCUP 2.04 +0.05(2.51%)
Will OCUP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for OCUP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OCUP
The Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue Estimates
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
OCUP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer
FDA Expands Merck's (MRK) Welireg Label in Renal Cell Carcinoma
Other News for OCUP
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
Ocuphire Pharma announces presentations on development of APX3330
Duos Technologies And 2 Other Stocks Under $3 Insiders Are Buying